Lung Cancer Clinical Trial
Clinical Study of Oral cMET Inhibitor INC280 in Adult Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (Geometry Mono-1)
Summary
A phase II study to evaluate antitumor activity of oral cMET inhibitor INC280 in adult patients with EGFR wild-type, advanced non-small cell lung cancer (NSCLC) as measured by overall response rate (ORR). The study will also evaluate safety and pharmacokinetics of INC280.
Eligibility Criteria
Inclusion Criteria:
Stage IIIB or IV NSCLC (any histology) at the time of study entry
Histologically or cytologically confirmed diagnosis of NSCLC that is:
EGFR wt as per patient standard of care by a validated test
AND ALK-negative rearrangement as part of the patient standard of care by a validated test
AND (by central assessment) either:
Cohort 1: Pre-treated patients with cMET GCN ≥ 6 or
Cohort 2: Pre-treated patients with cMET GCN ≥4 and < 6, or
Cohort 3: Pre-treated patients with cMET GCN < 4, or
Cohort 4: Pre-treated patients with cMET mutations regardless of cMET GCN, or
Cohort 5: Treatment-naïve patients with cMET dysregulation, or
Cohort 6: Pre-treated patients with either cMET GCN ≥ 10 without cMET mutations or cMET mutations regardless of cMET GCN, or
Cohort 7: Treatment-naïve patients with cMET mutations regardless of cMET GCN
To be eligible for Cohorts 1-4, patients must have failed one or two prior lines of systemic therapy for advanced/metastatic disease
To be eligible for Cohort 6, patients must have failed one prior line of systemic therapy for advanced/metastatic disease
To be eligible for Cohort 5 and Cohort 7, patients must not have received any systemic therapy for advanced/metastatic disease
At least one measurable lesion as defined by RECIST 1.1
Patients must have recovered from all toxicities related to prior anticancer therapies to grade ≤ 1 (CTCAE v 4.03). Patients with any grade of alopecia are allowed to enter the study.
Patients must have adequate organ function
ECOG performance status (PS) of 0 or 1 Details and other protocol-defined inclusion criteria may apply
Exclusion Criteria:
Prior treatment with crizotinib, or any other cMET or HGF inhibitor
Patients with characterized EGFR mutations that predict sensitivity to EGFR therapy, including, but not limited to exon 19 deletions and exon 21 mutations
Patients with characterized ALK-positive rearrangement
Clinically significant, uncontrolled heart diseases.
Patients receiving treatment with medications that cannot be discontinued at least 1 week prior to first INC280 treatment and for the duration of the study:
Strong inducers of CYP3A4
Impairment of GI function or GI disease that may significantly alter the absorption of INC280
Patients receiving treatment with any enzyme-inducing anticonvulsant
Applicable to Cohorts 1-4 and Cohort 6 only: Previous anti-cancer and investigational agents within 4 weeks or ≤ 5 x half-life of the agent (whichever is longer) before first dose
Pregnant or nursing women
Women of child-bearing potential, unless they are using highly effective methods of contraception
Sexually active males unless they use a condom during intercourse
Presence or history of interstitial lung disease or interstitial pneumonitis, including clinically significant radiation pneumonitis
Other protocol-defined exclusion criteria may apply
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 96 Locations for this study
Long Beach California, 90813, United States
Los Angeles California, 90095, United States
Orange California, 92868, United States
Tampa Florida, 33612, United States
Iowa City Iowa, 52242, United States
Boston Massachusetts, 02114, United States
Ann Arbor Michigan, 48105, United States
Rochester Minnesota, 55905, United States
Portland Oregon, 97239, United States
Allentown Pennsylvania, 18103, United States
Camp Hill Pennsylvania, 17011, United States
San Antonio Texas, 78229, United States
Salt Lake City Utah, 84103, United States
Caba Buenos Aires, C1426, Argentina
Buenos Aires Caba, C1431, Argentina
La Rioja , 5300, Argentina
Wien , 1210, Austria
Leuven , 3000, Belgium
Marseille cedex 20 Bouches Du Rhone, 13915, France
Dijon Cedex Cote D Or, 21034, France
Clermont-Ferrand , 63011, France
La Tronche , 38700, France
Lille , 59000, France
Marseille , 13273, France
Paris , 75970, France
Pierre Benite Cedex , 69495, France
Rennes , 35043, France
Strasbourg Cedex , 67091, France
Heidelberg Baden-Württemberg, 69126, Germany
Koeln Nordrhein-Westfalen, 50937, Germany
Berlin , 13125, Germany
Frankfurt , 60590, Germany
Gottingen , 37075, Germany
Halle (Saale) , 06120, Germany
Hamburg , 20251, Germany
Hannover , 30625, Germany
Homburg , 66421, Germany
Muenchen , 81925, Germany
Nuernberg , 90419, Germany
Ravensburg , 88214, Germany
Tübingen , 72076, Germany
Ulm , 89081, Germany
Ramat Gan , 52621, Israel
Tel Aviv , 64239, Israel
Bologna BO, 40138, Italy
Brescia BS, 25123, Italy
Catania CT, 95124, Italy
Catanzaro CZ, 88100, Italy
Meldola FC, 47014, Italy
Firenze FI, 50134, Italy
Monza MB, 20900, Italy
Milano MI, 20141, Italy
Milano MI, 20162, Italy
Modena MO, 41124, Italy
Roma RM, 00155, Italy
Verona VR, 37126, Italy
Napoli , 80131, Italy
Nagoya City Aichi, 464-8, Japan
Nagoya Aichi, 466-8, Japan
Kashiwa-City Chiba, 277-8, Japan
Minami-Ku Fukuoka, 811-1, Japan
Akashi-city Hyogo, 673-8, Japan
Sendai-city Miyagi, 980-0, Japan
Okayama-city Okayama, 700-8, Japan
OsakaSayama-city Osaka, 589-8, Japan
Chuo-ku Tokyo, 104-0, Japan
Koto ku Tokyo, 135 8, Japan
Ube-city Yamaguchi, 755-0, Japan
Bundang Gu Gyeonggi Do, 13620, Korea, Republic of
Gyeonggi do Korea, 10408, Korea, Republic of
Seoul , 03080, Korea, Republic of
Ashrafieh , 16683, Lebanon
Mexico Distrito Federal, 14080, Mexico
Amsterdam , 1066 , Netherlands
Groningen , 9713 , Netherlands
Maastricht , 6229 , Netherlands
Rotterdam , 3015 , Netherlands
Oslo , NO 04, Norway
Moscow , 10902, Russian Federation
Saint Petersburg , 19214, Russian Federation
Tambov , 39200, Russian Federation
Singapore , 11922, Singapore
Singapore , 16961, Singapore
Sevilla Andalucia, 41017, Spain
Oviedo Asturias, 33011, Spain
Barcelona Catalunya, 08035, Spain
Barcelona Catalunya, 08036, Spain
La Coruna Galicia, 15006, Spain
Madrid , 28034, Spain
Madrid , 28041, Spain
Stockholm , SE-17, Sweden
Kaohsiung , 82445, Taiwan
Taipei , 10002, Taiwan
Taoyuan , 33305, Taiwan
Birmingham , B9 5S, United Kingdom
London , W6 8R, United Kingdom
How clear is this clinincal trial information?